華海藥業(600521.SH):伏立康唑片擬中選第四批全國藥品集中採購
格隆匯 2 月 3日丨華海藥業(600521.SH)公佈,2021年2月3日,公司參加了國家組織藥品集中採購和使用聯合採購辦公室(“聯採辦”)組織的第四批全國藥品集中採購的投標工作,公司產品伏立康唑片擬中選本次集中採購。

2016年8月,公司向美國FDA(美國食品藥品監督管理局)申報的伏立康唑片新藥簡略申請獲得批准;2018年6月,公司獲得國家藥品監督管理局核准並簽發的伏立康唑片《藥品註冊批件》。2019年該產品國內市場實現銷售收入約5865.02萬元,佔2019年度營業收入的1.09%,2020年該產品國內市場實現銷售收入約6214.33萬元(該數據未經審計)。
此次藥品集中採購是國家組織的第四批國家藥品集中採購,在執行上要求醫療機構優先使用集中採購中選品種,並確保完成約定採購量。此次擬中選產品價格與原價相比有一定程度下降。若公司後續簽訂採購合同並實施後,將有利於該產品快速打開國內銷售市場,提高市場佔有率,促進公司製劑業務的進一步發展,提升公司的品牌影響力,對公司未來經營具有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.